Acridone-pyrimidine hybrids- design, synthesis, cytotoxicity studies in resistant and sensitive cancer cells and molecular docking studies
作者:Manikanta Murahari、Karanam Vanitha Prakash、Godefridus J. Peters、YC Mayur
DOI:10.1016/j.ejmech.2017.08.023
日期:2017.10
have identified 11a, 11b, 11d and 11h as potential inhibitors. Molecular docking studies identified the orientation and binding interactions at the active site of Akt1 and DNA. Compounds 12e and 12f have shown good cytotoxicity profile against lung cancer cell lines of sensitive and resistant type. Acute toxicity study of compound 12f at the dose of 5000 mg/kg has identified no signs of clinical toxicity
设计具有取代的嘧啶的a啶酮的杂化系统,其目的是发现靶向癌细胞中多种机制的下一代抗癌药。通过实验室中简便的方法合成了杂合化合物,并通过NMR和质谱方法进行了表征,并筛选了针对A549(肺癌),Hela(宫颈),MCF7(乳腺癌)和MDA-MB-231(乳腺癌)细胞的细胞毒性线。化合物对细胞增殖的评估可鉴定出活性化合物11b,11d和11h对抗MCF7,MDA-MB-231和A549细胞系。用CT-DNA进行进一步的吸收滴定和凝胶电泳确定,杂化分子部分通过DNA嵌入显示出抗癌活性。用Akt激酶进行的蛋白质印迹分析的其他结果还表明,杂合化合物具有抑制Akt激酶活性并诱导凋亡的能力,而ABCC1则表明活性化合物也具有调节与ABCC1 / MRP1相关的多药耐药性(MDR)的能力。选择性Akt1激酶测定已确定11a,11b,11d和11h为潜在抑制剂。分子对接研究确定了Akt1和DNA活性位点的方向